Danaher Corporation
$ 207.44
-0.92%
11 Aug - close price
- Market Cap 147,184,189,000 USD
- Current Price $ 207.44
- High / Low $ 208.44 / 206.09
- Stock P/E 36.48
- Book Value 74.81
- EPS 5.74
- Next Earning Report 2026-10-20
- Dividend Per Share $1.44
- Dividend Yield 0.7 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.08 %
- 52 Week High 241.78
- 52 Week Low 160.60
About
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Analyst Target Price
$227.96
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-21 | 2026-04-21 | 2026-01-28 | 2025-10-21 | 2025-07-22 | 2025-04-22 | 2025-01-29 | 2024-10-22 | 2024-07-23 | 2024-04-23 | 2024-01-30 | 2023-10-24 |
| Reported EPS | 1.94 | 2.06 | 2.23 | 1.89 | 1.8 | 1.88 | 2.14 | 1.71 | 1.72 | 1.92 | 2.09 | 2.02 |
| Estimated EPS | 1.84 | 1.94 | 2.19 | 1.72 | 1.64 | 1.64 | 2.16 | 1.57 | 1.57 | 1.71 | 1.91 | 1.88 |
| Surprise | 0.1 | 0.12 | 0.04 | 0.17 | 0.16 | 0.24 | -0.02 | 0.14 | 0.15 | 0.21 | 0.18 | 0.14 |
| Surprise Percentage | 5.4348% | 6.1856% | 1.8265% | 9.8837% | 9.7561% | 14.6341% | -0.9259% | 8.9172% | 9.5541% | 12.2807% | 9.4241% | 7.4468% |
Next Quarterly Earnings
| Sep 2026 | |
|---|---|
| Reported Date | 2026-10-20 |
| Fiscal Date Ending | 2026-09-30 |
| Estimated EPS | 1.91 |
| Currency | USD |
Previous Dividend Records
| Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-07-31 | 2026-04-24 | 2026-01-30 | 2025-10-31 | 2025-07-25 | 2025-04-25 | 2025-01-31 | 2024-10-25 | 2024-07-26 | 2024-04-26 |
| Amount | $0.4 | $0.4 | $0.32 | $0.32 | $0.32 | $0.32 | $0.27 | $0.27 | $0.27 | $0.27 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DHR
2026-08-11 10:41:03
Handelsbanken Fonder AB increased its stake in Danaher Corporation (NYSE:DHR) by 10.9% in the second quarter, bringing its total holdings to 289,223 shares valued at approximately $55.09 million. Institutional investors and hedge funds collectively own 79.05% of Danaher's stock, with other major investors like State Street Corp and Capital International Investors also adjusting their positions. Despite some recent target price reductions, analysts maintain a "Moderate Buy" consensus rating for Danaher, with an average price target of $228.91, following the company beating earnings estimates with revenue up 5.5% year over year.
2026-08-11 10:33:52
Handelsbanken Fonder AB has reduced its holdings in Thermo Fisher Scientific Inc. by 15.2% during the second quarter, selling 96,304 shares. Despite this, Thermo Fisher Scientific remains Handelsbanken Fonder AB's 19th largest holding, valued at approximately $269.99 million. The article also details recent institutional investor activity, positive news regarding FDA clearance and India growth for Thermo Fisher, as well as insider selling and analyst ratings.
2026-08-10 20:30:00
Danaher Corp. (DHR) shares rose 2.25% to $209.37 on a challenging trading day when the S&P 500 Index and Dow Jones Industrial Average both experienced declines. This marks the stock's fourth consecutive day of gains.
2026-08-10 16:40:39
Illumina stock (ILMN) has rallied 40% since January, reaching a 52-week high of $204 before settling at $188, driven by strong Q2 results and raised guidance, particularly in its clinical sequencing business. Wall Street analysts are now playing catch-up, revising their price targets upward, although the TIKR model suggests a more measured annualized return of 7% by December 2030, valuing ILMN at $254. The core of the investment thesis remains the sustained growth in clinical sequencing, supported by the NovaSeq X and increasing consumables revenue.
2026-08-09 11:01:39
Julie Sawyer Montgomery will become the new CEO of Danaher in October 2026, succeeding Rainer Blair, who will retire but remain as a senior advisor. Montgomery, who has been with Danaher since 2017 and oversaw significant growth in its Diagnostics business, will focus on accelerating innovation, enhancing business capabilities, and leveraging the Danaher Business System. Her appointment follows her critical role in integrating major acquisitions like Abcam and Masimo, signaling a strategic focus on commercial execution and expansion.
2026-08-08 18:20:38
Danaher Corporation has announced the appointment of Julie Sawyer Montgomery as its new President and Chief Executive Officer, effective October 1, 2026. She will also join the Board of Directors. Rainer Blair will retire and serve as a senior advisor to ensure a smooth transition. Ms. Sawyer Montgomery has significantly contributed to transforming Danaher's Diagnostics platform, growing its revenue and operating profit, and is expected to lead the company into its next phase of growth.
